Zydus today announced the launch of its novel dual PPAR agonist Lipaglyn
(saroglitazar) for treatment of diabetic dyslipidemia patients not controlled by
statin alone. Based on our physician survey / assessment of the drug profile /
market analysis, we expect Lipaglyn to garner around INR 650 million in peak
sales in India by 2016. We see the need of a fixed dose combination of Lipaglyn
with statin as important for the quick ramp up for this novel compound.
808, Real Tech Park, 8th Floor, Sector - 30A, Vashi, Navi Mumbai - 400703 , INDIA .
Telephone: +91 22 27810772, 27810773
Fax Number: +91 22 27812707
Follow Us On: